Group 1: Company Overview - The company, Minsheng Health, focuses on vitamins, minerals, probiotics, and therapeutic drugs, with a strong emphasis on expanding its product lines and market presence [2][3]. Group 2: Market Challenges and Strategies - The sales of vitamin and mineral products in offline channels have declined, but the impact on the company's OTC product, 21 Jinweita Multi-Element Tablets, is relatively limited [3]. - To address the challenges in pharmacy channels, the company plans to expand its terminal network and accelerate the launch of new products to become a leader in the vitamin and mineral sector [3]. Group 3: Probiotic Business Structure - The probiotic business is managed through subsidiaries, with teams split between Shandong for B2B sales and Hangzhou for B2C sales and R&D [3][4]. - The company has over 6,500 strains in its proprietary "Yanhuang Strain Library," with nearly 50 patented strains, focusing on functional strains with proven effects [3]. Group 4: Product Development and Target Markets - The company is developing products targeting both young and elderly consumers, with specific products for joint treatment and anti-aging aimed at the aging population [5][6]. - The company has plans for new product launches in areas such as joint treatment, anti-aging, and sleep improvement, although these require careful planning [6]. Group 5: Sales Dynamics - The company's revenue is concentrated in the first quarter due to inventory and accounts receivable clearance at year-end, leading to increased shipments to meet demand during the Spring Festival [6].
民生健康(301507) - 投资者关系活动记录表2025-007